Hyperfine
Hyperfine's revenue rose 5.2% to $14 million in fiscal 2025. Its operating margin was −273.4%, up from −335.3% a year earlier. Free cash flow was −$29 million. The diluted share count rose 13.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Hyperfine does
Hyperfine makes the Swoop system, a portable MRI scanner for the brain. MRI, or magnetic resonance imaging, takes pictures of the inside of the body without radiation. Conventional MRI machines are large, cost a lot and need special rooms and trained staff; the Swoop works at a much weaker magnetic field, can be wheeled to a patient's bedside, and is run from an iPad. It uses artificial intelligence software, which Hyperfine calls Optive AI, to clean up its images. A full brain scan takes around 25 minutes on average.
Hyperfine sells the scanner to hospitals and other care providers, mainly in the United States, together with an annual software, service and support agreement. Its first customers used it mostly in intensive care for children and adults, and it is now also selling it to neurology offices outside hospitals. The US Food and Drug Administration first cleared the Swoop in 2020 and has cleared new versions of its hardware and software since, most recently in December 2025. It is also approved for sale in the European Union, the United Kingdom, Canada, Australia, New Zealand and India.
A single contract manufacturer, Benchmark, assembles and supplies its finished products. Hyperfine had 102 full-time employees in February 2026, almost all in the United States.
Its biggest risks, as it describes them
- It has a history of losses and may not reach meaningful revenue or profit.
- Doctors and hospitals may not adopt its scanner, a new kind of product in a market that is changing fast.
- Its reliance on one contract manufacturer and a few suppliers to build its scanners.
- It may need to raise more money to fund sales, research and new products.
- Recalls or failing product quality standards could damage its reputation and cost it customers.
Income statement
Hyperfine lost money in fiscal 2025: a net loss of $36 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 188 | 118 | 75 | 38 | 35 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 12.6x | 14.6x | 10.1x | 6.2x | 4.3x |
| Quick ratio | 12.3x | 14.1x | 9.4x | 5.5x | 3.7x |
Cash flow
Projections
Project Hyperfine's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Hyperfine says to expect
- Full year 2026: revenue
Management continues to expect revenue for the full year 2026 to be approximately $20 to $22 million, representing 55% growth at the midpoint as compared to full year 2025.
- Full year 2026: net cash burn
Management continues to expect net cash burn 1 for the full year 2026 to be approximately $26 to $28 million, representing a 10% decline at the midpoint as compared to full year 2025.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Hyperfine shares on the open market, and 2 insiders sold $46,399.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Brett HaleCFO and CAO | Sold | 7,345 | $0.85 | $6,243 | Form 4 |
| May 26, 2026 | Thomas TeisseyreChief Operating Officer | Sold | 6,047 | $1.65 | $9,978 | Form 4 |
| Mar 23, 2026 | Brett HaleCFO and CAO | Sold | 24,188 | $1.21 | $29,267 | Form 4 |
| Feb 13, 2026 | Thomas TeisseyreChief Operating Officer | Sold | 821 | $1.11 | $911 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −324.4% | −286.9% | −209.6% |
| Altman Z'' | 2.41 | −11.00 | −16.31 |
| Accruals ratio | −2.1% | −2.5% | −13.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Hyperfine side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Hyperfine | FY25 | 5.2% | −273.4% | −214.8% | — | — | — | |
| CapsoVision | FY25 | 15.3% | −188.2% | −169.3% | — | — | — | Compare |
| Nano-X Imaging | FY25 | 15.4% | −600.8% | −345.6% | — | — | — | Compare |
| Elutia | FY25 | −15.0% | −218.9% | −379.8% | — | — | — | Compare |
| Profound Medical | FY25 | 50.7% | −256.3% | −238.4% | −304.9% | — | 5 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 0 | 2 | 7 | 11 | 13 | 14 |
| Revenue growth | — | 408.8% | 355.5% | 61.9% | 16.8% | 5.2% |
| Gross profit | −0 | −1 | 1 | 5 | 6 | 7 |
| Research and development | 15 | 26 | 28 | 22 | 22 | 18 |
| Operating income | −24 | −65 | −74 | −48 | −43 | −37 |
| Net income | −23 | −65 | −44 | −44 | −41 | −36 |
| Diluted EPS (US$) | −15.38 | −17.57 | −1.04 | −0.62 | −0.56 | −0.43 |
| Diluted shares (millions) | 2 | 4 | 70 | 71 | 72 | 82 |
| Cash flow | ||||||
| Cash from operations | −22 | −47 | −72 | −42 | −39 | −28 |
| Capital expenditure | 2 | 3 | 1 | 1 | 0 | 1 |
| Free cash flow | −23 | −50 | −73 | −43 | −39 | −29 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 7 | 11 | 5 | 4 | 3 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 63 | 188 | 118 | 75 | 38 | 35 |
| Debt incl. finance leases | 0 | — | — | — | — | — |
| Total assets | 72 | 202 | 134 | 94 | 59 | 55 |
| Total liabilities | 4 | 16 | 10 | 10 | 10 | 14 |
| Shareholders' equity | −61 | 186 | 124 | 84 | 49 | 41 |
| Margins and ratios | ||||||
| Gross margin | −162.2% | −78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Operating margin | −7,990.1% | −4,336.1% | −1,084.2% | −436.1% | −335.3% | −273.4% |
| Net margin | −7,968.4% | −4,335.0% | −649.2% | −401.0% | −315.9% | −262.3% |
| Free cash flow margin | −7,854.8% | −3,335.1% | −1,070.2% | −386.3% | −303.7% | −214.8% |
| Rule of 40 (growth + FCF margin) | — | −2,926.2% | −714.7% | −324.4% | −286.9% | −209.6% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −103.6% | −28.6% | −42.5% | −61.0% | −79.0% |
| Return on assets | — | −47.3% | −26.3% | −38.8% | −53.2% | −62.3% |
| Net debt to EBITDA | — | — | — | — | — | — |